EU agency says blood clot ‘rare’ J&J side effect
The Hindu
It believes benefits outweigh risks
Europe’s medicines regulator said on Tuesday that blood clots should be listed as a “very rare” side effect of Johnson & Johnson’s vaccine, but that the benefits of the shot still outweigh the risks. The United States is also expected to announce its decision on the single-shot J&J vaccine by Friday, as nations around the world urgently try to accelerate inoculation campaigns and revive their pandemic-ravaged economies. The European Medicines Agency (EMA) assessment came as an EU official promised to have enough doses available to vaccinate 70% of European adults by the summer — a boon for the continent’s sluggish rollout.More Related News